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Fluconazole (FLU), [2-(2-4-difluorophenyl]-
1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol], a syn-
thetic antifungal agent of the imidazole class, is sys-
temically used in oral, esophageal, and vaginal can-
didiasis, as well as in the treatment of cryptococcal
infections in patients with the acquired immunodefi-
ciency syndrome (AIDS). FLU interacts with 14-α
demethylase, a cytochrome P-450 enzyme necessary
to convert lanosterol to ergosterol-an essential com-
ponent of the fungal cell membrane. Fluconazole is
eliminated primarily by renal excretion, with
approximately 80% of the administered dose
appearing in the urine as unchanged drug (1-3).
Different analytical methods, for example, spec-
trophotometry (4, 5); capillary electrophoresis (6);
micellar electrokinetic capillary chromatography
(7); RP-HPLC (1, 3, 8), UPLC (9), or UPLC-
MS/MS (10); and gas chromatography (11, 12),
were reported for the determination of FLU in phar-
maceutical preparations and biological matrices.
The stability of active pharmaceutical ingredi-
ents (APIs) affects quality, efficacy and usage safe-
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ty of APIs. The chemical and physical stability eval-
uation process consists of many tests. These tests
should be conducted in a planned way following the
guidelines issued by ICH, WHO, or FDA (13-15).
The most important stability tests are stress tests,
which enable to identify degradation products. A list
of stress factors suggested for forced degradation
studies must include acid and base hydrolysis, ther-
mal degradation, photolysis, and oxidation (13). The
regulations do not specify the oxidation agents,
which should be used, in the case of oxidation. A
0.1ñ3% solutions of hydrogen peroxide are widely
used in forced degradation studies. Other chemicals
useful in oxidation reactions include, for example,
potassium permanganate (KMnO4), sodium
hypochlorite, singlet oxygen, or Fentonís reagent
(16).
KMnO4 is widely used as an oxidizing agent in
synthetic and in analytical chemistry and is also
applied as a disinfectant. It is effective over a wide
pH range. Potassium permanganate is the most
potent oxidation state both in alkaline and in acid
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mediums. KMnO4 can be used to differentiate degra-
dation products that can be related to drug and its
degradation products. Oxidation by permanganate
ion is applied in organic syntheses since the advent
of phase-transfer catalysis (17, 18).
There are reports in which FLU was subjected
to stress conditions of acid, alkali, and neutral
hydrolysis; oxidation; photolysis (in solutions and
solid phase); and thermal decomposition by RP-
HPLC. Extensive degradation was found to occur in
oxidative medium under thermal stress (19). The
forced oxidation degradation of FLU using hydro-
gen peroxide by spectrophotometric method was
performed (2). The literature survey also evidenced
the results of the stability of reconstituted FLU oral
suspension (20).
Shortage of information concerning reaction of
FLU with oxidants prompted us to investigate the
influence of KMnO4 on this drug stability. Herein,
we report on the development of a new UPLC-
MS/MS method for the determination of FLU and
its oxidation products during reaction with KMnO4
at the acidic pH. The method was used for kinetic
studies and identification of obtained degradation
products of FLU.
Chemicals and methods 
Chemicals and reagents
Fluconazole; 99.35%, SlovakoFarma, Batch
00/1040/01. HPLC grade glacial acetic acid was
purchased from AppliChem (Germany). HPLC
grade acetonitrile and formic acid (98%) were pur-
chased from J.T. Baker. HPLC grade water was
obtained from HLP 5 (HYDROLAB Poland) appa-
ratus and was filtered through 0.2 µm filter before
use. 
Standard solution 
The amount of 50.8 mg of FLU, weighed with
a precision of 0.1 mg, was dissolved in the volume
of 2.5 mL of glacial acetic acid and filled (up to the
25 mL) with dilution water. For method validation,
five solutions with concentration of 0.0609, 0.0812,
0.1015, 0.1218, and 0.1421 mg/mL of FLU were
prepared.
Oxidation study of the drug substance 
The amount of 0.5 mL of solution of FLU (2.03
mg/mL), 3.5 mL demineralized water, 1.0 mL of
concentrated sulfuric acid, 5.0 mL 0.02 M KMnO4,
and 5 µL of manganese dioxide solution was added
Table 1. Validation of the method.
Parameter Fluconazole  
tR (min) 6.22 ± 0.05
Limit of detection, [µg/mL] 4.10
Limit of quantitation, [µg/mL] 12.60
Linearity range, [mg/mL] 0.0609 ñ 0.1421
Regression coefficients a = 4696.7
P = a c + b ± Seb b = 6.7240
Standard deviation of the Sa = 53.54194
regression coefficients Sb = 5.64771
Correlation coefficient, R 0.9992
Determination coefficient, R2 0.9982
Normality of residualsc
(Shapiro-Wilk test) 
0.9493 (p = 0.5131)
level 50%: 0.56%
Precision (% RSD) level 100%: 0.63%
level 150%: 0.89%
level 50%: 0.93%
Indirect precision (% RSD) level 100%: 0.79%
level 150%: 1.02%
level 80%: 100.17%
Recovery [%] n = 3 level 100%: 99.67%
level 120%: 98.11%
aMean ± SD (n = 5). bP = peak area; c = concentration; a and b = regression coefficients, Se = standard error of
the estimate, Sa = standard deviation of the slope, Sb = standard deviation of the intercept, cNormal distribution
of residuals if p > 0.05, RSD = relative standard deviation.
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to 10.0 mL flasks. The test solutions were incubated
at room temperature and 1 µL of each reaction mix-
ture was injected onto ACQUITY UPLC system
after 36, 47, 54, 71, and 110 h, respectively.
Before the measurements of test samples, the
analysis of solutions containing identical compo-
nents as test samples but without KMnO4 was done.
The analyses were performed in triplicate.
UPLC/MS/MS analysis
The UPLC-MS/MS system consisted of a
Waters ACQUITYÆ UPLCÆ (Waters Corporation,
Milford, MA, USA) coupled to a Waters TQD mass
spectrometer (electrospray ionization mode ESI-tan-
dem quadrupole). Chromatographic separations
were carried out using the Acquity UPLC BEH
(bridged ethyl hybrid) C18 column; 2.1 ◊ 100 mm,
and 1.7 µm particle size, equipped with Acquity
UPLC BEH C18 VanGuard pre-column; 2.1 ◊ 5
mm, and 1.7 µm particle size. The column was
maintained at 40OC, and eluted under gradient con-
ditions from 100% to 50% of eluent A over 13 min,
at a flow rate of 0.3 mL/min. Eluent A: 0.1% (v/v)
formic acid in water; eluent B: 0.1% (v/v) formic
acid in acetonitrile. 1 µL of each sample was inject-
ed. Chromatograms were made using Waters eÎ
PDA detector. Spectra were analyzed in 200ñ700
nm range with 1.2 nm resolution and sampling rate
of 20 points/s.
MS detection settings of Waters TQD mass
spectrometer were as follows: source temperature
150OC, desolvation temperature 350OC, desolvation
gas flow rate 600 L/h, cone gas flow 100 L/h, capil-
lary potential 3.00 kV, cone potential 20 V.
Nitrogen was used for both nebulizing and drying
gas. The data were obtained in a scan mode ranging
from 50 to 1000 m/z in time 0.5 s intervals. 
Collision-activated dissociations (CAD) analy-
ses were carried out with the energy of 30 eV, and
all the fragmentations were observed in the source.
Consequently, the ion spectra were obtained by
scanning from 50 to 1000 m/z range. Data acquisi-
tion software was MassLynx V 4.1 (Waters).
Method validation
The described method was validated for the
determination of FLU in the presence of oxidation
products by UPLC method according to ICH guide-
lines (21).
Specificity
To demonstrate the specificity of the devel-
oped UPLC method the solution of FLU after oxi-
dation stress was analyzed. Oxidation study was
performed in KMnO4 solution at the acidic pH; the
solution was left for 15 min at room temperature.
Peak purity test was carried out for FLU peak by
using MS detector in a stressed sample.
Linearity
The calibration plot for the method was con-
structed by analysis of five solutions containing dif-
ferent concentrations of FLU in the range
0.0609ñ0.1421 mg/mL. Solutions were injected into
a column in the amounts of 1 µL. A further analyti-
cal procedure was as described in the UPLC
Conditions. Linearity was assessed in triplicate on
the basis of the relationship between peak areas and
concentration, in milligrams per milliliter. The lin-
ear coefficients, standard deviation of slope and
intercept, correlation coefficient R, determination
coefficient (R2), standard error of residuals of the
calibration curve and to determine whether the
residuals have a normal distribution, the Shapiro-
Figure 1. UPLC chromatogram overlay of FLU oxidation induced by KMnO4 in acidic conditions
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Wilk statistical test were calculated using the pro-
gram Statistica v. 10.
Limit of detection (LOD) and limit of quantifica-
tion (LOQ)
Based on the standard error of residuals (Se)
and the slope (a) of the calibration plot and follow-
ing the formula LOD = 3.3Se/a and LOQ = 10Se/a,
the LOD and LOQ for FLU was estimated.
Precision
The repeatability of the method was checked
by a threefold analysis of the three concentrations
levels 0.0508 mg/mL, 0.1015 mg/mL and 0.1523
mg/mL (50%, 100% and 150%) of FLU solutions.
The same protocol was followed for three different
days to study the intermediate precision of the pro-
posed method. Different analysts prepared different
solutions on different days. The RSD (%) of the
peak area of FLU was calculated.
Accuracy
The accuracy of the method was evaluated in
triplicate (n = 3) at the three concentrations of 0.0812,
0.1015 and 0.1218 mg/mL (80%, 100%, and 120%)
of FLU solutions, and the recovery was calculated for
each added (externally spiked) concentration.
Figure 2. MS/MS spectra of FLU and its degradation products: FP-2 and FP-3
Table 2. Kinetic results of FLU oxidation by KMnO4 in acidic media at room temperature.
Rate constant, t0.1 t0.5
k [h-1] [h]a [h]a 
Ra 
0.5626 1.85 16.69 0.9716  
at0.5 = half-life, t0.1 = time after which 10% of the substrate decomposes, and R = correlation coefficient.
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Robustness
To demonstrate the robustness of the method
deliberate small changes of flow rate, the content of
acetonitrile and column temperature were made
around the optimal values. The mobile phase flow
rate was 0.30 mL/min; to study the effect of the flow
rate on the resolution, the flow rate was changed to
0.27 and 0.33 mL/min. The effect of the column
temperature was studied at 36OC and 44OC (instead
of 40OC), and the mobile phase composition was
changed +10% from the initial composition. 
RESULT AND DISCUSSION
Result and discussion
ICH guideline requires stress testing to be per-
formed to elucidate the inherent stability character-
istics of the active substance (13). Ideal stability-
indicating method is one that quantifies the standard
drug alone without any interference from its degra-
dation products. For the separation and identifica-
tion of examined constituents and for the kinetic
studies of FLU in the presence of KMnO4 in acidic
Figure 3. The 1/ c = f(t) graph of oxidation of FLU by KMnO4 in acidic medium
Figure 4. Fragmentation pattern of product FLU
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solution, the developed and validated UPLC-
MS/MS method is suitable.
Optimization of chromatographic conditions
The UPLC/MS method was chosen to evaluate
the degradation process of FLU under potassium per-
manganate treatment in an acidic solution. With the
development of the chromatographic method enabling
the determination of FLU and its oxidation products, a
test procedure was started. After oxidation stress, the
FLU solution was analyzed. Satisfactory results were
achieved using gradient conditions from 100% to 0%
of water/formic acid (0.1%, v/v) over 13 min as eluent
A and acetonitrile/formic acid (0.1%, v/v) as eluent B,
at a flow rate of 0.3 mL/min. The retention time for
FLU in the developed condition was ≈ 6.22 min.
Method validation
The developed UPLC method was specific to
FLU and guaranteed to obtain well-shaped peaks
both for active substance and coexisting oxidation
products. Peaks of FLU were well resolved from
products FP-1, FP-2, FP-3 in chromatograms, and
no interference that could have an influence on the
obtained results was observed. 
Good linearity was observed in the concentra-
tion range 0.0609 ñ 0.1421 mg/mL of FLU. The cor-
relation coefficient and determination coefficient
(R2) obtained for the linear model were greater than
0.99. The y-intercept of the linear equation for FLU
was statistically insignificant. The distribution of the
residuals can be approximated with a normal distri-
bution as it is shown by the p-value (p > 0.05) of the
ShapiroñWilk normality test. Sensitivity of the
method was good. The limit of detection (LOD) and
limit of quantification (LOQ) values were found to
be 4.10 and 12.60 µg/mL, respectively. Accuracy of
the method expressed as % recovery at three con-
centration levels was from 98.11% to 100.17%.
Good precision and intermediate precision with %
RSD less than 1.02% was observed. Table 1 pres-
ents the detailed results. In all the deliberately varied
chromatographic conditions (flow rate, column tem-
perature, mobile phase composition), FLU and
Table 3. Proposed products of degradation of FLU.
Product Id tR [M+H]+ Fragmentation ions Proposed structure
70.0, 98.0, 139.0, 
FP-1 5.79 323.1 151.0, 169.0, 208.1,
220.1, 236.1, 305.1
70.0, 127.0, 139.0, 
FLU 6.22 307.1 151.0, 169.0, 220.1, 
238.1
FP-2 6.98 224.1 70.0, 127.0, 155.0
FP-3 7.54 159.0 -
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degradation products were adequately resolved, and
the order elution remained unchanged.
Oxidation of FLU by KMnO4 in acidic medium
The oxidative ability of KMnO4 depends on the
acidity of a reaction solution. The oxidation poten-
tial of KMnO4 decreases with increasing pH value
and counts +1.23 V at pH 3, and at pH 5, it reaches
+1.07 V; in neutral solution or in basic solution, it
was lower and equaled +0.58 V and +0.56 V,
respectively (22). Chromatograms obtained for acid
solution containing only FLU showed one peak with
retention time tR ≈ 6.22 min, whereas in chro-
matograms obtained for test solutions containing
KMnO4, with the addition of concentrated sulfuric
acid, three additional peaks of oxidation products of
FLU with retention times such as FP-1 tR ≈ 5.79,
FP-2 tR ≈ 6.98, and FP-3 tR ≈ 7.54 were observed
besides peak of FLU tR ≈ 6.22 min (Fig. 1). Figure 2
presents the MS/MS spectra of FLU and degradation
products such as FP-2 and FP-3. The degradation
process of FLU increased with the prolongation of
incubation time, and after 110 hours, decomposition
of FLU was 82.12%.
Kinetic evaluation
The analysis of the equation 1/c = f(t) for the oxi-
dation of FLU induced by KMnO4 under acidic condi-
Figure 5. Fragmentation pattern of product FP-1
Figure 6. Fragmentation pattern of product FP-2
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tions revealed that the process followed the kinetics of
second-order reaction (Fig. 3). Table 2 present the cal-
culated values of k, t0.1, and t0.5. The linear regression
equation was y = -11.41x + 0.5626. The correlation
coefficient and determination coefficient (R2) obtained
for linear model were found to be 0.9857 and 0.9716,
respectively. The standard deviation of slope and
intercept were 0.06 and 3.82, respectively.
Identification of oxidation products of FLU
The identification of photodegradation prod-
ucts of fluconazole was performed on a basis of
UPLC/MS analysis and supported with fragmenta-
tion patterns obtained from MS/MS experiments.
The structures of the proposed degradation products
are shown in Table 3. The structures of the present-
ed stable products of the degradation were proposed
on basis of the results of Collisionally Activated
Decomposition (CAD) experiments.
FLU was found at the retention time of 6.22
min with a molecular ion peak of m/z 307 in the pos-
itive mode. Methylene group was most susceptible
to oxidation in close vicinity to triazole moiety.
Hydroxylation of this group yielded product FP-1.
Further oxidation of this compound led to the loss of
triazolylmethylene moiety and dehydratation, as it is
observed in the case of product FP-2. Finally, degra-
dation of FP-2 involved loss of triazole-1-carbonyl
moiety and oxidation of methylene group to car-
boxylic group, yielding 2,4-difluorobenzoic acid
(FP-3). Figures 4-6 show the degradation patterns.
This quantity of degradation products found is the
largest compared with previously published papers
(2, 19). The proposed chemical structures of the oxi-
dation products shown in Table 3 are new, compared
to those reported in earlier publications. Azole com-
pounds, which are imidazole and triazole deriva-
tives, showed strong differences in their stability
(23-26). One of the most possible routs of degrada-
tion of azole antifungal drugs is hydroxylation that
can result in the ring opening or loss of imidazole
moiety as observed for, for example, clotrimazole or
bifonazole (23, 24). Similarly, in this case, hydroxy-
lation was the first step in the oxidative degradation
of FLU leading to FP-1. The product FP-2 at a reten-
tion time of 6.98 min and the molecular ion peak
(m/z 224) were the consequences of further hydroxy-
lation, which resulted in loss of one of triazole ring.
CONCLUSIONS
We have developed new stability indicating
UPLC-MS/MS method for the determination of
FLU and its oxidation products. The method meets
the acceptance criteria for validation and may be
used for the kinetic analysis of FLU oxidation. The
process followed kinetics of the second-order reac-
tion for the substrate. Finally, MS/MS experiments
allowed to determine that FLU oxidation results in
three derivatives.
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